Match!

Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.

Published on Jan 16, 2020in JCI insight6.014
· DOI :10.1172/JCI.INSIGHT.130362
Matthew R. Farren5
Estimated H-index: 5
,
Matthew R. Farren2
Estimated H-index: 2
(Emory University)
+ 12 AuthorsGregory B. Lesinski29
Estimated H-index: 29
Abstract
Pancreatic ductal adenocarcinoma (PDAC) has dismal 5-year survival (<9%). We hypothesize that exposure of tumors to conventional therapies may preferentially modulate immune biomarkers in the tumor microenvironment in PDAC. PDAC patients who underwent upfront surgical resection or who received neoadjuvant FOLFIRINOX with or without neoadjuvant radiotherapy followed by surgical resection were selected for study. Total expression of immunologically relevant transcripts and spatially resolved expression of immunologically relevant proteins was quantitated using multiplexed methods (NanoString nCounter and GeoMX platforms). This analysis identified numerous differentially expressed transcripts associated with the type of neoadjuvant therapy received. Moreover, we identified significant alterations in the expression and/or spatial distribution of immunologically relevant proteins in different regions (tumor cell rich, immune cell rich, stromal cell rich) of the tumor microenvironment. These data provide insight into the immunological effects of clinically relevant neoadjuvant therapy for resectable/borderline-resectable PDAC by describing significant differences in the expression of key immunologic biomarkers within the PDAC microenvironment that were associated with the type of treatment patients received prior to surgical resection. This represents a comprehensive analysis of numerous biomarkers conducted on the PDAC microenvironment. This work may guide strategic new combination therapies for pancreatic cancer.
  • References (31)
  • Citations (0)
📖 Papers frequently viewed together
1 Citations
20193.49The Breast
10 Authors (Ryungsa Kim, ..., Koji Arihiro)
78% of Scinapse members use related papers. After signing in, all features are FREE.
References31
Newest
#1Deli Hong (Harvard University)H-Index: 2
#2Andrew J. Fritz (UVM: University of Vermont)H-Index: 10
Last. Gary S. Stein (UVM: University of Vermont)H-Index: 106
view all 15 authors...
5 CitationsSource
#1Annie A. Wu (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 5
#2Elizabeth M. Jaffee (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 56
Last. Valerie Lee (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 3
view all 3 authors...
Purpose of Review Despite all efforts, pancreatic ductal adenocarcinoma (PDAC) remains a disease that causes substantial morbidity and mortality, with a 5-year survival rate of 7%. Innovative paradigms for treating PDAC are urgently needed.
2 CitationsSource
#1Mohamed A. ElTanbouly (Dartmouth College)H-Index: 2
#2Walburga Croteau (Dartmouth College)H-Index: 12
Last. J. Louise Lines (Dartmouth College)H-Index: 3
view all 4 authors...
Abstract V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint regulator with limited homology to other B7 family members. The constitutive expression of VISTA on both the myeloid and T lymphocyte lineages coupled to its important role in regulating innate and adaptive immune responses, qualifies VISTA to be a promising target for immunotherapeutic intervention. Studies have shown differential impact of agonistic and antagonistic targeting of VISTA, providing a unique landsca...
4 CitationsSource
#1Hany A. Omar (UOS: University of Sharjah)H-Index: 17
#2Mai F. Tolba (The: American University in Cairo)H-Index: 10
Abstract In the new era of immunotherapy, which has changed the clinical oncology practice guidelines, there is a pressing need for finding novel approaches to tune up the clinical outcomes of immunotherapy and extend its benefits to a wider cohort of cancer patients. Several non-classical molecular immune targets beyond PD-1/PD-L1 signaling were shown to be engaged as feedback resistance circuits to shut down the antitumor immune response mediated by the classical immune checkpoint inhibitors. ...
1 CitationsSource
#1Michel Ducreux (Université Paris-Saclay)H-Index: 85
#2Thomas Seufferlein (University of Ulm)H-Index: 32
Last. Thierry Conroy (University of Lorraine)H-Index: 45
view all 9 authors...
Abstract Pancreatic cancer is considered to be one of the most aggressive cancers. For unknown reasons, the incidence of pancreatic cancer is slowly rising and so too are mortality rates. Over 75% of patients are diagnosed with locally advanced disease or with metastases; and more than 95% of patients have metastases at diagnosis or will develop metastases during their follow-up. Despite recent improvements in the therapy of pancreatic cancer, initially with demonstration of the activity of the ...
Source
#1Alexander G. Raufi (CUMC: Columbia University Medical Center)H-Index: 2
#2Gulam Abbas Manji (CUMC: Columbia University Medical Center)H-Index: 4
Last. Susan E. Bates (CUMC: Columbia University Medical Center)H-Index: 5
view all 4 authors...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality rates. Currently, cure can only be achieved through resection, however the vast majority of patients present with advanced disease for which upfront surgery is not an option. In an effort to improve surgical candidacy, neoadjuvant chemotherapy, with or without radiation therapy, is often used in an effort to downstage borderline resectable and loc...
4 CitationsSource
#1Burak Uzunparmak (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Ibrahim Halil Sahin (Emory University)H-Index: 5
Pancreatic cancer is one of the leading causes of cancer-related death in the United States and survival outcomes remain dismal despite significant advances in molecular diagnostics and therapeutics in clinical practice. The microenvironment of pancreatic cancer carries unique features with increased desmoplastic reaction and is infiltrated by regulatory T cells and myeloid-derived suppressor cells which negatively impact the effector immune cells. Current evidence suggests that stellate cell-in...
2 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 47
#2Kimberly D. Miller (ACS: American Cancer Society)H-Index: 18
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 106
view all 3 authors...
990 CitationsSource
#1Begoña Ochoa (UPV/EHU: University of the Basque Country)H-Index: 19
#2Yolanda Chico (UPV/EHU: University of the Basque Country)H-Index: 9
Last. María José Martínez (UPV/EHU: University of the Basque Country)H-Index: 7
view all 3 authors...
The staphylococcal nuclease and Tudor domain containing 1 gene (SND1), also known as Tudor-SN, TSN or p100) encodes an evolutionarily conserved protein with invariant domain composition. SND1 contains four repeated staphylococcal nuclease domains and a single Tudor domain, which confer it endonuclease activity and extraordinary capacity for interacting with nucleic acids, individual proteins and protein complexes. Originally described as a transcriptional coactivator, SND1 plays fundamental role...
1 CitationsSource
#1Christian U. Blank (NKI-AVL: Netherlands Cancer Institute)H-Index: 50
#2Elisa A. Rozeman (NKI-AVL: Netherlands Cancer Institute)H-Index: 10
Last. Ton N. M. Schumacher (NKI-AVL: Netherlands Cancer Institute)H-Index: 61
view all 24 authors...
Adjuvant ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) both improve relapse-free survival of stage III melanoma patients1,2. In stage IV disease, the combination of ipilimumab + nivolumab is superior to ipilimumab alone and also appears to be more effective than nivolumab monotherapy3. Preclinical work suggests that neoadjuvant application of checkpoint inhibitors may be superior to adjuvant therapy4. To address this question and to test feasibility, 20 patients with palpable stage III mela...
62 CitationsSource
Cited By0
Newest